Q-omics provides the consensus-scored TAMALIN profile across patient tissues and cancer cell-line models. TAMALIN expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TAMALIN is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, TAMALIN RNA expression shows 17,308 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight UVM, BLCA, and CCRCC as cancer lineages where TAMALIN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAMALIN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAMALIN survival associations across molecular data types. TAMALIN RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAMALIN RNA expression–survival associations across cancer types. High TAMALIN expression shows unfavorable associations in UVM, KIRP and COAD, but favorable associations in HNSC, KIRC and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TAMALIN RNA expression.
This table summarizes TAMALIN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TAMALIN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAMALIN shows lower tumor expression in BLCA, LUAD, KIRP, KICH, COAD and LUSC. The BLCA box plot shows higher TAMALIN RNA expression in normal versus tumor tissue (log2 FC = −1.812, t-test p < 0.001).
This table shows molecular features associated with TAMALIN in patient tissues and cancer cell lines. In patient samples, TAMALIN shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TAMALIN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
